New Approaches to the Prevention of Lung Tumor Recurrence Following
Surgical Resection
Mark W. Grinstaff
Departments of Biomedical Engineering and Chemistry, Boston University,
Boston, MA
mgrin@bu.edu
http://people.bu.edu/mgrin
The most effective treatment for stage I patients with localized non-small cell lung
cancer (NSCLC) is surgical resection. However, if disease recurs, the long-term
survival is dismal with a 2-year survival of only ≈20%. The risk of local recurrence
in early stage lung cancer is greater in patients receiving smaller sublobar
resection compared to larger lobectomy. At the surgical resection margin,
residual microscopic tumor cells remain and are present in ≈40% of patients
following a “curative” wedge resection, demonstrating a need to treat those
remaining cancer cells. We have designed, synthesized, and evaluated three
types of polymeric drug delivery devices (nanoparticles, hydrophobic films, and
superhydrophobic meshes), which can be implanted at the time of resection
surgery. Specifically, I will discuss the: 1) synthesis of these materials; 2)
material properties; 3) in vitro cytotoxicity; and 4) in vivo performance as well as
the advantages and limitations of each of these approaches using nanoparticles,
hydrophobic films, or superhydrophobic meshes towards preventing tumor
recurrence following surgery.
Recent Publications:
Journal of the American Chemical Society, 2009, 131, 2469-2471.
Annals of Surgical Oncology, 2010, 17, 1203-1213.
Journal of Controlled Release, 2010, 144, 280-287.
ChemMedChem, 2010, 5, 1435-1438.
Journal of Controlled Release, 2012, 159, 14-26.
Molecular Pharmaceutics, 2012, 9, 196-200.
Biomacromolecules, 2012, 13, 406-411.
Journal of the American Chemical Society, 2012, 134, 2016-2019.
Journal of Controlled Release, 2012, 162, 92-101.
Journal of the American College of Surgeons, 2012, 214, 328-337.